Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report

BACKGROUND: CDK4/6 inhibitors (CDKi), namely, palbociclib, ribociclib, and abemaciclib, combined with either an aromatase inhibitor (AI) or fulvestrant are the standard first/second line for hormone receptor-positive(HR+)/HER2-negative(neg) metastatic breast cancer (MBC). However, the choice of one...

Descripción completa

Detalles Bibliográficos
Autores principales: Schettini, Francesco, Seguí, Elia, Conte, Benedetta, Sanfeliu, Esther, Gonzalez-Farre, Blanca, Jares, Pedro, Vidal-Sicart, Sergi, Ganau, Sergi, Cebrecos, Isaac, Brasó-Maristany, Fara, Muñoz, Montserrat, Prat, Aleix, Vidal, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679790/
https://www.ncbi.nlm.nih.gov/pubmed/36425558
http://dx.doi.org/10.3389/fonc.2022.1009352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679790/
https://www.ncbi.nlm.nih.gov/pubmed/36425558
http://dx.doi.org/10.3389/fonc.2022.1009352

Ejemplares similares